Allen Institute Funds $200M Brain Disease Gene Therapy Effort
TL;DR. The Allen Institute commits $200 million to a new Brain Health Accelerator focused on developing gene therapies for neurodegenerative diseases. - This marks the institute's first venture into direct disease treatment, building on its brain mapping research. - The initiative aims to target specific cells and circuits affected by conditions like Alzheimer's and Parkinson's. - Initial funding comes from the Fund for Science and Technology, established by Paul Allen's estate.
- Allen Institute launches Brain Health Accelerator with $200M funding.
- Goal is to develop gene therapies for neurodegenerative diseases (e.g., Alzheimer's, Parkinson's).
- First time the institute's mission extends to treating disease.
- Initiative will target affected cells and circuits rather than proteins.
- Funding from Paul Allen's estate, supplemented by federal grants and future partnerships.